The House Committee on Oversight and Government Reform has opened an investigation into whether the three largest pharmacy benefit managers in the United States punished independent pharmacies for supporting legislation to rein them in — and on Friday, 30 October 2026, the committee’s deadline for the companies to sit down for staff-level briefings arrived. Chairman James Comer, a Kentucky Republican, announced the inquiry on 23 October, writing to CVS Caremark, Express Scripts and Optum Rx with a blunt concern: that independent pharmacies which publicly backed a bipartisan bill to change how pharmacy benefit managers, or PBMs, are paid were then hit with an unusual surge of burdensome audits. The companies have not been found to have retaliated — the investigation is at the document-request stage — but the committee says the pattern it has been shown is serious enough to demand the firms’ internal records.
To understand the dispute, it helps to understand what a PBM does. When a patient fills a prescription, the PBM sits between the pharmacy, the insurer and the drug manufacturer: it negotiates prices, builds lists of covered drugs, processes claims and reimburses the pharmacy. The three firms named in the inquiry dominate that middle layer, and independent pharmacists have complained for years that the terms they are offered — low reimbursements, fees clawed back after the sale, and audits that can demand repayment months later — make it hard for small pharmacies to survive. The committee’s investigation is the latest chapter in a fight that Comer has pursued since 2021, and it turns on a specific question: were the audits that followed a July vote on reform legislation routine oversight, or were they timed to intimidate?
The PBM audit retaliation allegations at the heart of the probe
The bill at the centre of the story is H.R. 6610, the Pharmacists Fight Back in FEHB Plans Act, which the Oversight Committee advanced in July 2026. For pharmacies serving federal employees under the Federal Employees Health Benefits programme, the bill would require PBMs to pay a benchmark price with a capped margin, plus a dispensing fee aligned with what the state Medicaid programme pays — a structure its supporters say would stop PBMs from paying pharmacies below cost and pocketing the difference. More than 60 state and national pharmacy groups supported the bill, many of them based in Kentucky, Mississippi and Florida, the three states the committee has singled out in its document requests.
According to the committee, the trouble started after that July markup. In Comer’s words, “multiple independent pharmacies that supported the Committee’s efforts have received an unusual number of burdensome audit notices in short succession from several PBMs. This raises concern that these audit notices were sent or timed to retaliate for their support of H.R. 6610.” The committee cited striking examples: one audit tied to a medication costing $0.99 that consumed hundreds of hours of pharmacy staff time, and audit notices carrying compliance deadlines dated before the pharmacy even received them. Those details, if accurate, describe something very different from a routine paperwork check — they describe an audit process being used as a burden in itself, where the cost of complying becomes the punishment regardless of the outcome.
What the committee is demanding from the three PBM giants
The letters to the three companies ask for documents, communications and staff-level briefings covering their audit practices in detail: how pharmacies are selected for audits, what the nationwide audit totals have been since 22 July 2026, and every audit of an independent pharmacy in Kentucky, Mississippi and Florida, including the reason for each audit and its result. The committee asked for the staff briefings promptly and no later than 30 October, with written responses due by 6 November. The requests also cover all audit types — desk audits, in-person audits, unannounced audits and compliance audits — and ask for the totals broken down between PBM-affiliated pharmacies and unaffiliated ones, a distinction that matters because critics have long argued that PBMs treat their own pharmacies more gently than their competitors.
The committee also pointed to a warning sign from earlier in the year. In June 2026, it said, the Florida Attorney General’s office responded to concerns about efforts by CVS Caremark to impose undue burdens through the audit process — an episode the committee treats as part of a pattern rather than an isolated complaint. And the inquiry builds on a previous Oversight Committee report, cited in the committee’s announcement, which concluded that the three firms exercise significant influence over drug pricing through market tactics that raise costs and undermine community pharmacies, and which called for legislative reforms to improve transparency. Comer’s public summary of the new investigation was unsparing: PBMs, he said, “must not be allowed to weaponize the audit process to punish pharmacies that support greater transparency, lower prescription drug costs, and stronger protections for patients,” and the committee “will follow the facts and determine whether these audits were legitimate or were used to intimidate independent pharmacists.”
Why independent pharmacies say audits can be a weapon
For a small pharmacy, an audit is not an abstraction. A PBM audit typically demands records for a batch of prescriptions — prescriber details, delivery signatures, inventory logs — and if the pharmacy cannot produce a document to the auditor’s satisfaction, the PBM can claw back the reimbursement it already paid, sometimes months after the medicine was dispensed. A single audit can therefore cost a small business staff hours it cannot spare and money it has already spent on stock. When several audits arrive at once, as the committee says happened to pharmacies that backed H.R. 6610, the effect compounds: the pharmacy is forced to choose between serving patients and satisfying auditors, and the financial risk grows with every claim under review.
That vulnerability is why the timing question matters so much. Audits are, in themselves, a legitimate tool — every payer in American health care audits claims to catch billing errors and fraud, and no one in the committee’s announcement argues otherwise. The allegation is narrower and more specific: that the selection and timing of these audits changed after the pharmacies took a public political position, and that the burden was disproportionate to the sums involved, as in the $0.99 medication case. If the documents show that pattern, the committee’s supporters say, it would be evidence of retaliation against protected advocacy. If they show that audit rates were steady and that the pharmacies were selected by neutral criteria, the companies will have a strong answer. That is the factual contest the document requests are designed to settle, and it is why the committee has asked for the underlying selection data rather than relying on either side’s characterisation.
The PBM industry’s side of the argument
The companies’ public positions so far have been limited, and it is important to be precise about what has and has not been said. A CVS spokesperson confirmed to one trade publication that the company had received Comer’s letter and planned to respond to the committee — a procedural acknowledgement, not a substantive defence. The Pharmaceutical Care Management Association, the trade group that represents PBMs, pushed back against H.R. 6610 itself during the July markup, arguing against the bill’s payment structure, but that opposition to legislation is a different matter from the audit question, and the committee’s letters do not claim the trade group’s lobbying was improper. No finding has been made against any of the three firms, and the investigation’s central claim — retaliation — remains, at this stage, an allegation the committee says it is testing, not a conclusion it has reached.
The broader industry argument, made in earlier PBM debates, is that audits and payment controls are how PBMs keep drug spending in check for employers and taxpayers, and that restricting them would raise costs. Supporters of reform reply that the savings from those controls flow disproportionately to the PBMs themselves, which both manage benefits and own large pharmacy chains — a vertical integration that gives them an interest in squeezing independent competitors. That structural tension is the backdrop to the whole inquiry: the same companies that decide what pharmacies are paid also compete with those pharmacies, audit them, and, under H.R. 6610, would face new limits on what they can charge. Whether the audit surge was retaliation or coincidence cannot be settled by that structural argument alone, which is why the committee wants the records.
What happens after the October 30 briefing deadline
The immediate next step is the briefings themselves and the written responses due on 6 November. If the companies comply fully, the committee will have the data to compare audit rates before and after the July markup, to test whether pharmacies that supported the bill were audited more heavily than those that did not, and to examine whether deadlines and demands in individual cases were reasonable. If the companies resist or produce only partial records, the committee has the usual tools of congressional oversight — further letters, public hearings, and ultimately subpoenas — though each escalation would itself become a political fight, and the companies would be able to argue in public that the inquiry is itself an attempt to pressure them over legislation.
The stakes extend beyond three companies and one bill. Independent pharmacies have been closing across rural America for years, and their advocates argue that each closure leaves patients — often older, often on multiple prescriptions — with fewer choices and longer journeys for care. PBM reform has drawn bipartisan support in Congress precisely because it touches both parties’ constituencies: rural Republican districts losing their only pharmacy, and Democratic concerns about corporate concentration in health care. H.R. 6610 itself covers only federal employee plans, a limited slice of the market, but its supporters treat it as a template for wider reform, and its opponents treat it the same way. The audit investigation, whatever it finds, will therefore be read as a test case: whether Congress can police the line between legitimate oversight of pharmacies and the use of oversight as leverage against the people who dare to ask Congress for help.
Sources
USN reviewed reporting from multiple outlets for this story. Read more from House Committee on Oversight and Government Reform, Fierce Healthcare and Becker’s Hospital Review.